You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 29, 2025

Claims for Patent: 10,519,241

✉ Email this page to a colleague

Summary for Patent: 10,519,241

Title:	Antibody constructs for EGFRVIII and CD3
Abstract:	The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human EGFRVIII on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Inventor(s):	Tobias Raum, Ines Herrmann, Patrick Hoffmann, Peter Kufer, Markus Muenz, Doris Rau
Assignee:	Amgen Research Munich GmbH
Application Number:	US15/225,627

Details for Patent 10,519,241

Glossary

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	TALTZ	ixekizumab	Injection	125521	March 22, 2016	⤷ Get Started Free	2036-08-01
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 10,519,241

Subscribe to access the full database, or Get Started Free
Country	Patent Number	Estimated Expiration
South Africa	201804514	⤷ Get Started Free
South Africa	201708306	⤷ Get Started Free
South Africa	201707816	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2017134140	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2017021370	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2017021362	⤷ Get Started Free
World Intellectual Property Organization (WIPO)	2017021356	⤷ Get Started Free
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.